SCHEMBL7654136

SCHEMBL7654136

CC(=O)On1ncc2cc3[nH]c(=O)c(-c4cn(CCCN)c5cc(OCc6ccccc6)ccc45)nc3cc21

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.39
TRPM8 Q7Z2W7 1/20 0.34
IGF1R P08069 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
FGFR1 P11362 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR3 P22607 1/20 0.34
CAMK2D Q13557 4/20 0.34
GRM4 Q14833 1/20 0.33
CHEK1 O14757 1/20 0.33
CHEK2 O96017 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
PRMT5 O14744 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7655905 0.95 EGLN1 (0.39) EGLN1TRPM8IGF1RFGFR1FGFR2
Acetic Acid SCHEMBL7654019 0.89 EGLN1 (0.40) EGLN1TRPM8IGF1RCNR1CNR2
SCHEMBL7657220 0.88 CAMK2D (0.42) CAMK2D
SCHEMBL7661373 0.87 TRPM8 (0.34) EGLN1TRPM8IGF1RCNR1CNR2
Acetic Acid SCHEMBL7654130 0.85 EGLN1 (0.38) EGLN1TRPM8IGF1RCNR1CNR2
SCHEMBL7837818 0.85 EGLN1 (0.36) EGLN1TRPM8IGF1RCNR1CNR2
Acetic Acid SCHEMBL7837822 0.85 CHEK1 (0.38) EGLN1TRPM8IGF1RCNR1CNR2
Acetic Acid SCHEMBL7817717 0.85 EGLN1 (0.40) EGLN1TRPM8IGF1RCNR1CNR2
Acetic Acid SCHEMBL7817718 0.85 CAMK2D (0.39) EGLN1TRPM8IGF1RCNR1CNR2
Acetic Acid SCHEMBL8368547 0.85 EGLN1 (0.48) EGLN1IGF1RCAMK2DCHEK1CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US disclosed